Provectus Biopharmaceuticals, Inc.
PVCT · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -79.4% | 1,844.1% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | 99.2% | -36.6% | 96.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -3,132% | -393.7% | -16,285.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -3,222.1% | -409.1% | -16,724.1% |
| EPS Diluted | -0.003 | -0.004 | -0.003 | -0.006 |
| % Growth | 27.9% | -59.3% | 52.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |